This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

OncoMed Pharmaceuticals Initiates Third Phase 1b Clinical Trial Of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) With Nab-Paclitaxel (Abraxane(R)) And Gemcitabine In Stage IV Pancreatic Cancer

REDWOOD CITY, Calif., Dec. 4, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it has started a Phase 1b clinical trial of its first-in-class Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane ®) and gemcitabine in patients with Stage IV pancreatic cancer. This trial is the third of three Phase 1b trials for vantictumab initiated this year as part of OncoMed's collaboration with Bayer Pharma AG.  

The multi-center Phase 1b clinical trial is a dose escalation study that will evaluate safety of vantictumab in combination with Abraxane and gemcitabine and determine a recommended Phase 2 dose for this combination regimen.  Key secondary and exploratory objectives include evaluation of the pharmacokinetics (PK) of vantictumab, as well as the pharmacodynamics (PD) and efficacy of this combination.  Tumor tissue from patients will be used to explore predictive biomarker hypotheses related to the efficacy of vantictumab.

"Incidence of pancreatic cancer has been steadily rising. In spite of recent advancements, metastatic pancreatic cancer represents a significant unmet medical need and patients are in need of improved treatment options," said Safi Shahda, M.D., Assistant Professor of Clinical Medicine at Indiana University in Indianapolis, IN, and the Principal Investigator who treated the first patient enrolled in this study. "By targeting cancer stem cells, vantictumab has the potential to augment the clinical benefit of standard chemotherapy in this disease setting. I am particularly excited by the inclusion of biomarker measures in this Phase 1b trial of vantictumab with Abraxane and gemcitabine, which will provide valuable information related to the drug's mechanism of action." 

The other investigators and clinical sites to participate in the trial are: Jordan Berlin, M.D., Vanderbilt University, Nashville, TN; Steven Cohen, M.D., Fox Chase Cancer Center, Philadelphia, PA; Heinz-Josef Lenz, M.D., University of Southern California, Los Angeles, CA, and Wells Messersmith, M.D., University of Colorado Cancer Center, Aurora, CO.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs